Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$174.4M
32M shares
52-week range
$2.33 – $8.51
50% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.2M | $2.2M | $958.0K | $1.5M | $1.9M | $4.1M |
| Cost of revenue | $559.0K | $344.0K | $1.9M | $778.0K | $976.0K | $1.1M | $1.1M | $3.9M |
| Gross profit | −$559.0K | −$344.0K | −$639.0K | $1.4M | −$18.0K | $413.0K | $740.0K | $190.0K |
| Gross margin | — | — | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| R&D | $6.5M | $6.8M | $9.8M | $5.0M | $7.3M | $9.3M | $9.8M | $15.9M |
| Operating income | −$15.2M | −$22.2M | −$29.7M | −$53.7M | −$18.0M | −$25.1M | −$61.0M | −$30.6M |
| EBITDA | −$15.2M | −$21.9M | −$30.5M | −$48.5M | −$13.3M | −$23.1M | −$59.0M | −$47.9M |
| Net income | −$15.8M | −$22.3M | −$29.9M | −$64.1M | −$72.9M | −$27.8M | −$60.7M | −$50.2M |
| Net margin | — | — | -2461.5% | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (diluted) | -8.32 | -8.71 | -9.14 | -14.40 | -20.00 | -3.75 | -4.66 | -1.65 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.83 | $-1.39–$-0.00 | 2 |
| 2027 | $8M | $-0.85 | $-1.41–$-0.00 | 2 |
| 2028 | $29M | $-0.79 | $-1.31–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
www.imdxinc.comNo one on the platform currently holds IMDX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 13,400 | $100.5K |
No one on the platform has traded IMDX yet.
| $278M |
| — |
Source: Financial Modeling Prep · peers by sector/industry
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/06-22-2026-190745705
View on StockTwits ↗$IMDX released data showing its GraftAssure CM-score outperforms single‑metric dd‑cfDNA in kidney transplant rejection detection.
View on StockTwits ↗IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/06-11-2026-211734810
View on StockTwits ↗$IMDX great analysis out of seeking alpha and comments 20+ target
View on StockTwits ↗$IMDX added more here today. We’re about 2 months out from the 150 day guideline from the FDA…I think we bounce over $15 when approved. Jmho
View on StockTwits ↗iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress $IMDX https://finance.yahoo.com/sectors/healthcare/articles/imdx-highlight-house-transplant-testing-200500649.html
View on StockTwits ↗$IMDX news 06/09/26 IMDX /to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress Jun 09, 2026 Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing
View on StockTwits ↗$IMDX very few on this, for a stock headed for $25. I am the mayor of this group.
View on StockTwits ↗@Monkey7779192 full port into $IMDX and thank me in 90 days
View on StockTwits ↗$IMDX bought a little more. Neil B and I own 40% of this company now.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.